Venturi Wealth Management LLC Sells 6,528 Shares of Abbott Laboratories $ABT

Venturi Wealth Management LLC trimmed its stake in shares of Abbott Laboratories (NYSE:ABT) by 28.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,588 shares of the healthcare product maker’s stock after selling 6,528 shares during the quarter. Venturi Wealth Management LLC’s holdings in Abbott Laboratories were worth $1,703,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in ABT. Crown Wealth Group LLC boosted its stake in shares of Abbott Laboratories by 13.4% in the 1st quarter. Crown Wealth Group LLC now owns 2,523 shares of the healthcare product maker’s stock valued at $259,000 after purchasing an additional 298 shares during the last quarter. Powers Advisory Group LLC raised its stake in Abbott Laboratories by 6.2% during the first quarter. Powers Advisory Group LLC now owns 3,281 shares of the healthcare product maker’s stock worth $337,000 after buying an additional 191 shares during the last quarter. VCI Wealth Management LLC raised its stake in Abbott Laboratories by 65.3% during the first quarter. VCI Wealth Management LLC now owns 19,128 shares of the healthcare product maker’s stock worth $1,964,000 after buying an additional 7,557 shares during the last quarter. Welch Group LLC lifted its holdings in Abbott Laboratories by 9.5% in the first quarter. Welch Group LLC now owns 88,991 shares of the healthcare product maker’s stock valued at $9,137,000 after buying an additional 7,706 shares during the period. Finally, Waterway Wealth Management LLC bought a new stake in Abbott Laboratories during the first quarter valued at $1,012,000. 75.18% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This represents a 0.15% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Up 0.8%

NYSE:ABT opened at $94.02 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a market cap of $163.77 billion, a PE ratio of 26.34, a PEG ratio of 1.62 and a beta of 0.63. The firm has a 50-day moving average of $89.08 and a 200-day moving average of $105.38.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. Abbott Laboratories’s payout ratio is presently 70.59%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ABT shares. Barclays lowered their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Argus cut their target price on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Jefferies Financial Group lowered their target price on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a report on Friday, April 17th. Oppenheimer dropped their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, The Goldman Sachs Group reduced their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $118.30.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.